Literature DB >> 1689140

Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.

D P van Kammen1, J Peters, J Yao, W B van Kammen, T Neylan, D Shaw, M Linnoila.   

Abstract

In recent years the dopamine hypothesis has failed to explain the complexities of schizophrenia. Because both negative symptoms and noradrenergic activity appear to increase with psychotic relapse, we studied negative symptoms, psychosis, cerebrospinal fluid norepinephrine, and cerebrospinal fluid monoamine metabolites in 32 male patients with a DSM-III diagnosis of schizophrenia while both receiving and not receiving long-term haloperidol treatment. Drug-free cerebrospinal fluid norepinephrine and 3-methoxy-4-hydroxyphenylglycol levels correlated significantly with the severity of negative symptoms and psychosis ratings. When the patients were divided into those who did and did not relapse while not receiving the drug, significant positive correlations between negative symptoms and cerebrospinal fluid norepinephrine and 3-methoxy-4-hydroxyphenylglycol were observed only in the patients who relapsed. Non significant but negative correlations were observed between the same variables in the nonrelapsers. Thus, increased norepinephrine activity in drug-free patients is associated with intensification of schizophrenic symptoms without necessarily causing the symptoms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689140     DOI: 10.1001/archpsyc.1990.01810140061009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  8 in total

1.  Role of Norepinephrine in Schizophrenia: An Old Theory Applied to a New Case in Emergency Medicine.

Authors:  Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2020-07-01

2.  Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat.

Authors:  J Grenhoff; M Nisell; S Ferré; G Aston-Jones; T H Svensson
Journal:  J Neural Transm Gen Sect       Date:  1993

3.  Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia.

Authors:  Igor Elman; David Rott; Alan I Green; Daniel D Langleben; Scott E Lukas; David S Goldstein; Alan Breier
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

4.  Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.

Authors:  Mary E Kelley; Gretchen L Haas; Daniel P van Kammen
Journal:  Schizophr Res       Date:  2008-07-11       Impact factor: 4.939

Review 5.  Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition.

Authors:  J T Coull
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

6.  The effect of chronic chlorpromazine administration on monoamine levels in various regions of rat brain.

Authors:  M H Baf; M N Subhash; K M Lakshmana; B S Rao
Journal:  Neurochem Res       Date:  1995-01       Impact factor: 3.996

Review 7.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

8.  Vitamin B6 deficiency hyperactivates the noradrenergic system, leading to social deficits and cognitive impairment.

Authors:  Kazuya Toriumi; Mitsuhiro Miyashita; Kazuhiro Suzuki; Nao Yamasaki; Misako Yasumura; Yasue Horiuchi; Akane Yoshikawa; Mai Asakura; Noriyoshi Usui; Masanari Itokawa; Makoto Arai
Journal:  Transl Psychiatry       Date:  2021-05-03       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.